Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Fennec to $20 from $18 and keeps a Buy rating on the shares. Fennec’s Q4 revenues were at the high end of the pre-released range and Craig-Hallum sees an exciting and profitable year ahead, with the stock not yet fully pricing in the EU deal, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FENC:
- Fennec Pharmaceuticals Files SEC 8-K Report
- Fennec Pharmaceuticals’ Soaring Sales and New Deal
- Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
- Fennec reports Q4 EPS (10c), consensus (2c)
- Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
